Hydrocortisone decreases lethality and inflammatory cytokine and nitric oxide production in rats challenged with B. anthracis cell wall peptidoglycan.
Anti-inflammatory agents
B. anthracis
Cell wall
Corticosteroids
Peptidoglycan
Shock
TNF-soluble receptor
Journal
Intensive care medicine experimental
ISSN: 2197-425X
Titre abrégé: Intensive Care Med Exp
Pays: Germany
ID NLM: 101645149
Informations de publication
Date de publication:
18 Nov 2020
18 Nov 2020
Historique:
received:
24
06
2020
accepted:
06
11
2020
entrez:
18
11
2020
pubmed:
19
11
2020
medline:
19
11
2020
Statut:
epublish
Résumé
Lethal B. anthracis infection produces high proinflammatory peptidoglycan (PGN) burdens in hosts. We investigated whether the lethality and inflammation anthrax PGN can produce are related. At 6 h before and the start of 24 h anthrax PGN infusions, rats (n = 198) were treated with diluent (controls) or one of three IV-doses of either hydrocortisone (125, 12.5 or 1.25 mg/kg) or TNF-soluble receptor (TNFsr; 2000, 1000 or 333 μg/kg), non-selective and selective anti-inflammatory agents, respectively. Compared to controls, hydrocortisone 125 and 12.5 mg/kg each decreased 7-day lethality (p ≤ 0.004). Hydrocortisone 125 mg/kg decreased IL-1β, IL-6, TNFα, MCP, MIP-1α, MIP-2, RANTES and nitric oxide (NO) blood levels at 4 and 24 h after starting PGN (except MCP at 24 h). Each decrease was significant at 4 h (except MIP-1α that was significant at 24 h) (p ≤ 0.05). Similarly, hydrocortisone 12.5 mg/kg decreased each measure at 4, 24 and 48 h (except TNFα at 24 h and MIP-1α at 24 and 48 h and NO at 48 h). Decreases were significant for IL-6 and NO at 4 h and RANTES at 48 h (p ≤ 0.05). Hydrocortisone 1.25 mg/kg had non-significant effects. Each TNFsr dose decreased lethality but non-significantly. However, when doses were analyzed together, TNFsr decreased lethality in a potential trend (p = 0.16) and IL-6 and NO significantly at 4 h (p = 0.05). Peptidoglycan-stimulated host inflammation may contribute to B. anthracis lethality.
Sections du résumé
BACKGROUND
BACKGROUND
Lethal B. anthracis infection produces high proinflammatory peptidoglycan (PGN) burdens in hosts. We investigated whether the lethality and inflammation anthrax PGN can produce are related.
METHODS
METHODS
At 6 h before and the start of 24 h anthrax PGN infusions, rats (n = 198) were treated with diluent (controls) or one of three IV-doses of either hydrocortisone (125, 12.5 or 1.25 mg/kg) or TNF-soluble receptor (TNFsr; 2000, 1000 or 333 μg/kg), non-selective and selective anti-inflammatory agents, respectively.
RESULTS
RESULTS
Compared to controls, hydrocortisone 125 and 12.5 mg/kg each decreased 7-day lethality (p ≤ 0.004). Hydrocortisone 125 mg/kg decreased IL-1β, IL-6, TNFα, MCP, MIP-1α, MIP-2, RANTES and nitric oxide (NO) blood levels at 4 and 24 h after starting PGN (except MCP at 24 h). Each decrease was significant at 4 h (except MIP-1α that was significant at 24 h) (p ≤ 0.05). Similarly, hydrocortisone 12.5 mg/kg decreased each measure at 4, 24 and 48 h (except TNFα at 24 h and MIP-1α at 24 and 48 h and NO at 48 h). Decreases were significant for IL-6 and NO at 4 h and RANTES at 48 h (p ≤ 0.05). Hydrocortisone 1.25 mg/kg had non-significant effects. Each TNFsr dose decreased lethality but non-significantly. However, when doses were analyzed together, TNFsr decreased lethality in a potential trend (p = 0.16) and IL-6 and NO significantly at 4 h (p = 0.05).
CONCLUSIONS
CONCLUSIONS
Peptidoglycan-stimulated host inflammation may contribute to B. anthracis lethality.
Identifiants
pubmed: 33206255
doi: 10.1186/s40635-020-00358-4
pii: 10.1186/s40635-020-00358-4
pmc: PMC7674536
doi:
Types de publication
Journal Article
Langues
eng
Pagination
67Références
Am J Physiol Lung Cell Mol Physiol. 2001 Nov;281(5):L1037-50
pubmed: 11597894
Vet Pathol. 2010 Sep;47(5):819-30
pubmed: 20656900
FEBS Lett. 1999 Nov 26;462(1-2):199-204
pubmed: 10580119
J Infect Dis. 2010 Dec 15;202(12):1885-96
pubmed: 21067373
J Basic Clin Pharm. 2016 Mar;7(2):27-31
pubmed: 27057123
Hypertension. 1992 Jun;19(6 Pt 1):567-74
pubmed: 1592452
J Rheumatol. 1994 Mar;21(3):430-4
pubmed: 7911833
Cell Microbiol. 2008 Jan;10(1):1-8
pubmed: 17944960
J Infect Dis. 2007 Feb 15;195(4):572-80
pubmed: 17230417
Joint Bone Spine. 2015 Oct;82(5):330-7
pubmed: 25864942
Intensive Care Med. 2011 Oct;37(10):1688-95
pubmed: 21922303
Infect Immun. 2001 Feb;69(2):1175-7
pubmed: 11160016
J Immunol. 2011 Apr 1;186(7):3841-5
pubmed: 21357534
Intensive Care Med. 2010 Jan;36(1):148-56
pubmed: 19756496
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1333-41
pubmed: 21852539
Am J Pathol. 2006 Aug;169(2):433-44
pubmed: 16877346
J Clin Endocrinol Metab. 2014 Jun;99(6):2269-76
pubmed: 24606100
J Cell Mol Med. 2013 Jul;17(7):914-20
pubmed: 23742651
N Engl J Med. 2015 Mar 5;372(10):954-62
pubmed: 25738671
Expert Rev Mol Med. 2009 Jun 30;11:e19
pubmed: 19563700
Biochim Biophys Acta. 2015 Jan;1852(1):104-19
pubmed: 25445540
FASEB J. 2002 Jan;16(1):61-71
pubmed: 11772937
Infect Immun. 2009 Oct;77(10):4529-37
pubmed: 19620350
Microbes Infect. 2008 Oct;10(12-13):1244-50
pubmed: 18678270
Cell. 1988 Apr 22;53(2):211-7
pubmed: 3129195
FEMS Microbiol Lett. 1991 Aug 15;66(3):257-62
pubmed: 1769521
Blood. 2018 Aug 23;132(8):849-860
pubmed: 29921614
Crit Care Med. 1999 Apr;27(4):723-32
pubmed: 10321661
Ann Intern Med. 2004 Jul 6;141(1):47-56
pubmed: 15238370
N Engl J Med. 2005 Oct 20;353(16):1711-23
pubmed: 16236742
Br J Pharmacol. 1996 Dec;119(7):1411-21
pubmed: 8968550
Am J Physiol Regul Integr Comp Physiol. 2004 Apr;286(4):R699-709
pubmed: 14715494
J Infect Dis. 2013 Sep;208(6):978-89
pubmed: 23737601
Am J Physiol Lung Cell Mol Physiol. 2006 Apr;290(4):L622-L645
pubmed: 16531564
Cell Mol Life Sci. 2017 Jun;74(11):1985-1997
pubmed: 28154894
Blood. 2007 Feb 1;109(3):1265-74
pubmed: 17018861
J Infect Dis. 2006 Mar 15;193(6):829-40
pubmed: 16479518
Mod Pathol. 2001 May;14(5):482-95
pubmed: 11353060
PLoS One. 2008;3(11):e3706
pubmed: 19002259
J Biol Chem. 2005 May 27;280(21):20177-80
pubmed: 15802263
J Infect Dis. 2011 Aug 1;204(3):348-57
pubmed: 21742832
J Biol Chem. 2004 Feb 20;279(8):6629-34
pubmed: 14660668
Toxins (Basel). 2017 Dec 06;9(12):
pubmed: 29210983
Chest. 2009 Dec;136(6):1631-1643
pubmed: 19801579
BMC Med. 2013 Oct 09;11:217
pubmed: 24107194
Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2291-4
pubmed: 8460135
Nat Rev Microbiol. 2008 Apr;6(4):276-87
pubmed: 18327271
Emerg Infect Dis. 2014 Sep;20(9):1452-63
pubmed: 25148307
Emerg Infect Dis. 2014 Feb;20(2):
pubmed: 24447897
Emerg Infect Dis. 2017 Jan;23(1):56-65
pubmed: 27983504
Korean J Intern Med. 2014 Nov;29(6):807-13
pubmed: 25378980
Am J Physiol Heart Circ Physiol. 2019 May 1;316(5):H1076-H1090
pubmed: 30767685
Infect Immun. 2010 Jun;78(6):2418-28
pubmed: 20308305
Emerg Infect Dis. 2001 Nov-Dec;7(6):933-44
pubmed: 11747719